How did Arcus Biosciences' revenue and expenses trend in Q4 2024?

Arcus Biosciences experienced a significant increase in revenue, with a 38% year-over-year growth, reaching $258 million. However, the company's research and development (R&D) expenses also rose, climbing 23% to $448 million. Unfortunately, the company reported a net loss of $283 million for the quarter, indicating that despite revenue growth, the company's expenses, particularly in R&D, outpaced their revenue, leading to financial losses.

|code|Ticker|Name|Date|Total Revenue (FY)|R&D Expenses (FY)|Net Income (FY)|market_code|
|---|---|---|---|---|---|---|---|
|RCUS|RCUS.N|Arcus Biosciences|2024|2.58E8|4.48E8|-2.83E8|169|